Remove 2019 Remove Hospitals Remove Labelling
article thumbnail

Once-daily cystic fibrosis treatment recommended by NICE

Hospital Pharmacy Europe

‘Access to a once-daily treatment at home can make an enormous difference to patients and their families – reducing the burden of hospital appointments and allowing children and young people to live more freely and independently. The post Once-daily cystic fibrosis treatment recommended by NICE appeared first on Hospital Pharmacy Europe.

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Although no formal contraindications are listed in AstraZeneca’s US labeling, perioperative management may require holding acalabrutinib 3 to 7 days before and after surgery to minimize bleeding risk. November 21, 2019. Hepatotoxicity and drug-induced liver injury are additional risks that require monitoring. 2024;22(4):22-29.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmacist to Clinical Strategy Leader: Brendan Doran on Building a Career in Biotech

The Nontraditional Pharmacist

So, we would have spoken in 2019. And those are sites, sometimes those are hospitals, sometimes they’re physician’s offices, there’s for-profit, clinical research sites out there. So, good talking to you. Matt Paterini (01:21): No, we appreciate the time. And remember, COVID was in there too, right? It’s 2025.

FDA
article thumbnail

A pharmacist’s take on actions from the child asthma and anaphylaxis deaths report

Hospital Pharmacy Europe

Key findings in this review emphasised that most of these children and young people died before reaching the hospital, with 46% receiving inadequate asthma care. Some deaths occurred due to cardiac arrest, predominantly outside of hospitals, with 29 children (58%) having unsuccessful cardiopulmonary resuscitation.

article thumbnail

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Pharmacy Times

Tafamidis, a selective transthyretin stabilizer, significantly reduces mortality and hospitalizations in ATTR-CM patients. Tafamidis] was compared to placebo and reduced all-cause mortality by 30% and [cardiovascular] hospitalizations by 32% over 30 months.

article thumbnail

Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs

PharmTech

Thakar Varanya Chaiyaperm View All News Article Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling. Part two discussion describes a simple medication order and demonstrates calculations and labeling for each bulk drug type. Pluta Nishant B. Mole calculations.

article thumbnail

Gabapentin Use Linked to Increased Dementia Risk in Chronic Back Pain Patients

Pharmacy Times

1 Image Credit: Syahrir | stock.adobe.com Gabapentin is FDA approved for partial seizures and postherpetic neuralgia, but has widespread off-label use for various chronic pain conditions, including back pain. Published December 2019. Subscribe Now!